EWA
NKTR icon

EverSource Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

EverSource Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.99K Buy
111
+1
+0.9% +$57 ﹤0.01% 3037
2025
Q4 		$4.65K Hold
110
– – ﹤0.01% 3155
2025
Q3 		$6.26K Sell
110
-700
-86% -$23.2K ﹤0.01% 3048
2025
Q2 		$20.9K Buy
810
+717
+771% +$8.05K ﹤0.01% 2252
2025
Q1 		$945 Buy
93
+82
+745% +$1.07K ﹤0.01% 3248
2024
Q4 		$159 Buy
+11
New +$194 ﹤0.01% 3476
2022
Q2 		– Sell
-31
Closed -$3K – 1833
2022
Q1 		$3K Buy
31
+11
+55% +$1.63K ﹤0.01% 1433
2021
Q4 		$4K Buy
+20
New +$4.34K ﹤0.01% 1348

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EverSource Wealth Advisors's NKTR Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Nektar Therapeutics (NKTR) stake by 0.91% in Q1 2026, buying an estimated $57 and bringing the position to 111 shares worth $7.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3037.

EverSource Wealth Advisors first reported a position in NKTR in Q4 2021 and has held it in 8 quarters since. The position peaked at $20.9K in Q2 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • EverSource Wealth Advisors held 111 shares of Nektar Therapeutics worth $7.99K as of Q1 2026.
  • EverSource Wealth Advisors bought 1 Nektar Therapeutics share in Q1 2026, an estimated $57.
  • Nektar Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3037 holding.
  • EverSource Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • EverSource Wealth Advisors's Nektar Therapeutics position peaked at $20.9K in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.